Introduction and Objective: To characterize people with T1D (pwT1D) using CGM and the proportion meeting glycemic targets (time in range [TIR], time above and below range, coefficient of variation [CV], and glucose management indicator [GMI]) over time.Methods: A retrospective observational study was conducted using TriNetX’s Electronic Health Record (EHR) and linking it to Glooko’s CGM data (1 January 2015 – 30 June 2024). Descriptive analyses were performed to contextualize glycemic control and EHR coded hypoglycemic events (E-HEs) in the United States. Results were stratified by the presence of E-HEs and follow-up duration.Results: A total of 3,533 pwT1D used CGM, mean age was 41.4 yrs, with 61% female, 89% White and 4.5% Hispanic. Among those with 1yr of follow-up, annualized rate of E-HEs was 0.64 at baseline and 0.56 at 1yr, with majority of E-HEs occurring in outpatient setting. At baseline, 25% had HbA1c <7% compared to 35% after 1yr. The proportion achieving CGM targets were similar between baseline and 1yr, with < 35% achieving TIR >70% (Table 1). Those with ≥1 HEs had higher HbA1c, more comorbidities, infections, and greater health care utilization but similar CGM metrics compared to those without HEs.Conclusion: PwT1D using CGM have inadequate glycemic control with continued E-HEs, highlighting the need for novel treatments for T1D.
V.N. Shah: Consultant; Dexcom, Inc. Advisory Panel; Sanofi, Novo Nordisk. Consultant; Lilly Diabetes. Advisory Panel; embecta. Consultant; Insulet Corporation. Advisory Panel; Tandem Diabetes Care, Inc, Ascensia Diabetes Care. Research Support; Enable Bioscience. Consultant; Genomelink and Lumosfit. R.L. Molinsky: Employee; Vertex Pharmaceuticals Incorporated. T. Pakalapati: Employee; Vertex Pharmaceuticals Incorporated. J. Sherwood: Employee; Vertex Pharmaceuticals.
Source link
Leave a Reply